Conclusion While Retatrutide holds exciting promise, it is not yet available for prescription use
Seeing blood in the toilet, on toilet paper, or mixed with a bowel movement can be alarming
Clinical research context: Large clinical trials of FDA-approved branded injectable semaglutide (conducted under controlled conditions) reported an average body weight reduction of approximately 14.9% from baseline to week 68, compared to 2.4% with placebo
Chiquette E, Toth PP, Ramirez G, Cobble M, Chilton R: Treatment with exenatide once weekly or twice daily for 30 weeks is associated with changes in several cardiovascular risk markers
Where AOD 9604 may show more pronounced results is in the context of a structured program that includes caloric management, resistance training, and potentially stacked peptide protocols